Entellus Medical Inc. (ENTL) Stock News
NASDAQ:ENTL - Nasdaq -
ENTL Latest News, Press Relases and Analysis
Axon Therapies Appoints Industry Veteran Brian Farley to Board of Directors
/PRNewswire/ -- Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced the appointment of Brian Farley to the...
Mentions: VNUS
Entellus Medical, Inc. (ENTL): Downgrade News
ENTL – William Blair downgrades to Hold. Stock price at the time of this analyst call was $23.99.
Entellus Medical, Inc. (ENTL): Earnings News
ENTL – Beats Wall Street consensus EPS estimates by $0.36 and beats on revenues.
Entellus Medical, Inc. (ENTL): Stock Offering News
ENTL – Files for 10,226,165 share common stock offering by holders.
The Law Offices of Vincent Wong Notifies Investors of a Complaint on Behalf of Entellus Medical, Inc. Shareholders Concerning the Sale of the Company to Stryker Corporation – ENTL
ACT NOW: Monteverde & Associates PC Announces An Investigation Of Entellus Medical, Inc. - ENTL
Entellus Medical, Inc. (ENTL): Earnings News
ENTL – Misses EPS loss estimates by $0.03. Beats on revenues.
Entellus Medical, Inc. (ENTL): Guidance Up News
ENTL – Sees FY17 revs of $91.5-94.5 mln vs. $89.85 mln.
The Law Offices of Vincent Wong Notifies Investors of an Investigation of Entellus Medical, Inc. Concerning the Sale of the Company to Stryker Corporation
ENTELLUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entellus Medical, Inc.
Mentions: SYK
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entellus Medical, Inc.
Wall Street's M&A Chatter From December 7: Entellus Medical-Stryker, Sucampo, Silicon Labs-Sigma Designs
The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday, Dec. 7, 2017. Entellus Medical to be Acquired by Stryker for $24.00/Share in Cash...
ENTELLUS MEDICAL, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
32 Biggest Movers From Yesterday
Gainers SAGE Therapeutics Inc (NASDAQ: SAGE) shares climbed 70.04 percent to close at $156.27 on Thursday after the company disclosed that Phase 2 trial of SAGE-217 met its...
Why Entellus Medical Inc. Skyrocketed Higher Today
The medical device company is getting acquired. Could a higher offer be in the works?
Mentions: SYK
Entellus Medical, Inc. (ENTL): M&A News
ENTL – Entellus Medical to be acquired by Stryker for $24.00/share in cash or an equity value of approximately $662 million.
Entellus Medical, Inc. (ENTL): Product News News
ENTL – Anthem now covers the treatment of chronic and recurrent acute sinusitis by balloon sinus dilation, a procedure done by Entellus Medical’s XprESS line of devices.
Entellus Medical, Inc. (ENTL): Product News News
ENTL – Announces data from study of the Latera absorbable nasal implant from Spirox.
The VP Marketing of Entellus Medical (NASDAQ: ENTL) is Buying Shares
Today, the VP Marketing of Entellus Medical (NASDAQ: ENTL), Kevin Mensink, bought shares of ENTL for $3,100. Following this transaction Kevin Mensink’s holding in the company was increased by 33.33% to a total of $136.5K. Based on Entellus Medical’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $22.14
The post The VP Marketing of Entellus Medical (NASDAQ: ENTL) is Buying Shares appeared first on Analyst Ratings.
Entellus Medical, Inc. (ENTL): Neutral Rating Reiterated
ENTL – Canaccord Genuity reiterates Hold rating, $17 PT. This price target represents a -9.28% downside over the stock’s previous closing price of $18.74.
.jpg)
Canaccord Genuity Reiterates a Hold Rating on Entellus Medical
Canaccord Genuity analyst Jason Mills reiterated a Hold rating on Entellus Medical (NASDAQ: ENTL) yesterday and set a price target of $17. The company’s shares opened today at $18.77. According to TipRanks.com, Mills is a top 100 analyst with an average return of 20.6% and a 71.8% success rate. Mills covers the Healthcare sector, focusing
The post Canaccord Genuity Reiterates a Hold Rating on Entellus Medical appeared first on Analyst Ratings.
Entellus Medical Receives a New Rating from Top Analyst
Piper Jaffray analyst Matthew O’Brien reiterated a Buy rating on Entellus Medical (NASDAQ: ENTL) yesterday and set a price target of $21. The company’s shares opened today at $17.32. According to TipRanks.com, O’Brien is a top 100 analyst with an average return of 22.6% and a 67.0% success rate. O’Brien covers the Healthcare sector, focusing
The post Entellus Medical Receives a New Rating from Top Analyst appeared first on Analyst Ratings.
Premarket Biotech Digest – CELG Inks New Deal, LLY Gets Favorable Ruling, ALR Modifies Deal
Celgene Corporation announced that it has agreed to acquire a stake in BeiGene. The deal has valued BeiGene stock at $4.58 apiece.
Entellus Medical, Inc. (ENTL): Acquisition News
ENTL – Enters agreement to acquire Spirox a privately-held ENT medical technology company that develops, manufactures and markets the LATERA Absorbable Nasal Implant.